Visual Acuity

Although best corrected visual acuity was the only visual function test ready for immediate use in a diabetic retinal disease staging system, others showed promise or potential, according to a report published in Ophthalmology Science.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Gemmy Cheung, MD, PhD, expresses satisfaction with the effects of sozinibercept in patients with polypoidal choroidal vasculopathy, or PCV.

EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating Duravyu for patients with diabetic macular edema, according to a press release.

Science Corporation reported positive preliminary results of a clinical trial examining its Prima retinal implant in patients with central visual field loss due to geographic atrophy.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Douglas Love, president and CEO of Annexon Biosciences, discusses the company’s phase 3 program in geographic atrophy.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Timothy L. Jackson, PhD, MBChB, discusses phase 2b trial results of sozinibercept for neovascular age-related macular degeneration.

CARLSBAD, Calif. — A sustained-release intravitreal hydrogel implant containing axitinib demonstrated durable results in patients with neovascular age-related macular degeneration, according to phase 1 study results.

BARCELONA, Spain — A subgroup analysis of the DAVIO 2 trial showed that eyes implanted with the EYP-1901 intravitreal insert maintained stable visual acuity with strong anatomic control over 8 months, according to a presenter.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina meeting, Francesco Boscia, MD, discusses the role of new anti-VEGF agents in the treatment of pigment epithelial detachment.

In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.